Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

Pulmonary angiography, specifically the computed tomographic version, is the gold standard for diagnosing lung embolism.